1-3 of 3
Rula Zain
Close
Sort by
Journal Articles

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function

H. Yesid Estupiñán, Thibault Bouderlique, Chenfei He, Anna Berglöf, Andrea Cappelleri, Nicolai Frengen, Rula Zain, Mikael C. I. Karlsson, Robert Månsson, C. I. Edvard Smith
Journal: Blood Advances
Blood Adv (2024) 8 (8): 1981–1990.
https://doi.org/10.1182/bloodadvances.2024012706
Published: 2024
Includes: Supplemental data
Journal Articles

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, C. I. Edvard Smith, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1929–1943.
https://doi.org/10.1182/bloodadvances.2022008447
Published: 2023
Includes: Supplemental data
Journal Articles

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects

H. Yesid Estupiñán, Thibault Bouderlique, Chenfei He, Anna Berglöf, Dhanu Gupta, Osama Saher, Miguel Ángel Daza Cruz, Lucia Peña-Perez, Liang Yu, Rula Zain, Mikael C. I. Karlsson, Robert Månsson, C. I. Edvard Smith
Journal: Blood Advances
Blood Adv (2020) 4 (11): 2439–2450.
https://doi.org/10.1182/bloodadvances.2019001319
Published: 2020
Includes: Supplemental data